Skip to main content
Clinical Trials/CTRI/2024/09/073569
CTRI/2024/09/073569
Not yet recruiting
Not Applicable

To evaluate and compare the invivo safety and efficacy of Skin Care Formulation verses Untreated Control in terms of skin moisturization and skin barrier function on healthy human subjects

G.D. Pharmaceuticals Pvt. Ltd.1 site in 1 country33 target enrollmentStarted: September 15, 2024Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
G.D. Pharmaceuticals Pvt. Ltd.
Enrollment
33
Locations
1
Primary Endpoint
Skin moisturization and skin barrier function

Overview

Brief Summary

OBJECTIVE- The objective of this study will be to evaluate and compare the in-vivo safety and efficacy of Skin Care Formulation verses Untreated Control in terms of skin moisturization and skin barrier function on healthy human subjects.

The evaluation is performed using: Subject Self Evaluation, Dermatological Evaluation: Cosmetic Acceptability, Dermatological Evaluation:Efficacy, Corneometry, Tewametry.

 The study lasts 2 days following the first application of the product on the forearm.

POPULATION- 33(16/17 males & 16/17 Female) subjects will be selected for the study .

The subjects selected for this study are healthy male & female, aged between 18 and 40 years old, having dry skin type.

STUDY DURATION-Duration: 24 hours following the first application of the product.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Participant Blinded

Eligibility Criteria

Ages
18.00 Year(s) to 40.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Indian subjects 2)Healthy subjects 3)Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar) 4)Subject having dry skin type.

Exclusion Criteria

  • Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
  • Having refused to give her/his assent by not signing the consent form
  • Taking part in another study liable to interfere with this study
  • Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months)
  • Having a progressive asthma (either under treatment or last fit in the last 2 years)
  • Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area (except for specific studies on a determined dermatosis)
  • Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months)
  • Being epileptic.
  • Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol)
  • Having cutaneous hypersensitivity.

Outcomes

Primary Outcomes

Skin moisturization and skin barrier function

Time Frame: Baseline, 30 Minutes, 24 Hours

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
G.D. Pharmaceuticals Pvt. Ltd.
Sponsor Class
Other [Fast-Moving Consumer Goods]
Responsible Party
Principal Investigator
Principal Investigator

Dr Pooja Yadav

MASCOT-SPINCONTROL India Pvt. Ltd.

Study Sites (1)

Loading locations...

Similar Trials